Adubação nitrogenada de sorgo granífero consorciado com capim em sistema de plantio direto

O objetivo deste trabalho foi avaliar o efeito do manejo da adubação nitrogenada sobre a cultura do sorgo granífero, cultivado solteiro e em consócio com capim-marandu e capim-mombaça, e determinar a produtividade de matéria seca das forrageiras, nos anos agrícolas 2003/2004 e 2004/2005, em plantio direto. Foi utilizado o delineamento experimental em blocos ao acaso, em arranjo fatorial 3x5, com quatro repetições. Os tratamentos consistiram de três sistemas de cultivo de sorgo granífero (solteiro e consorciado com capim-marandu ou capim-mombaça, na linha de semeadura) e cinco manejos de adubação nitrogenada: 30-70; 70-30; 50-50; 100-0; e 0-100 kg ha-1 de N, quantidades aplicadas na semeadura e na cobertura, respectivamente. O cultivo consorciado não afetou a nutrição nem a produtividade de grãos de sorgo. Apenas no primeiro ano de cultivo, o parcelamento 50-50 kg ha-1 de N proporcionou maior produtividade de grãos. O manejo da palhada interferiu no estabelecimento do sorgo no segundo ano de cultivo, e diminuiu a produtividade de grãos. As maiores doses de N aplicadas em cobertura elevaram a produtividade de matéria seca do capim-marandu e, as aplicadas em semeadura, a elevaram no capim-mombaça

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

BACKGROUND: A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. METHODS: This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. FINDINGS: Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0-75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4-97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8-80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3-4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. INTERPRETATION: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials. FUNDING: UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Lemann Foundation, Rede D'Or, Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Background A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. Methods This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. Findings Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0–75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4–97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8–80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3–4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. Interpretation ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials

Damper-to-damper path loss characterization for intra-vehicular wireless sensor networks

Intra-Vehicular Wireless Sensor Networks (IVWSNs) is one of the major advances in electrical smart cars. It could extend the driving distance of E-cars by reducing the weight of bulky cables. It can also bring more sensing functions, turning the car into smart units for Intelligent Transportation Systems (ITS). Until now, most works of IVWSNs channel characterization are focused on in-car wireless communication. This paper presents for the first time, to author's knowledge, the channel characterization of a non-line-of-sight damper-to-damper wireless communication at 2.4 GHz frequency band, including the signal reflection from ground. A method of 3D EM simulation is provided. Static and dynamic on-field car measurement is also performed on a commercial car with different road profiles. It shows that different road profiles equally impact path loss specification because of similar permittivity. From on-field measurements, it proves that 5.25 MHz frequency isolation leads to uncorrelated channels

Relationship between raindrops and ultrasonic energy on the disruption of a Haplic Cambisol Relação entre energia de gotas de chuva e energia ultra-sônica na desagregação de um Cambissolo Háplico

The aim of this work was to compare aggregate disruption of undisturbed soil samples by ultrasonic energy to aggregate disruption caused by the energy of simulated raindrops, to provide equations that can describe this relationship, and to evaluate whether aggregate stability, expressed by sonication method, may be used to estimate the effect that raindrops have on undisturbed soil samples. Undisturbed soil samples from A, Bi and C horizons of a Cambisol were submitted to different levels of ultrasonic energy and simulated raindrops. Sieved samples (aggregates) were also submitted to different levels of ultrasonic energy so that both disturbed and undisturbed conditions of samples could be compared. The results showed that the method using ultrasonic energy on undisturbed soil samples can simulate the amount of aggregate disruption of soil due to raindrop impact. Dispersion curves of disturbed samples may not be used to estimate the effect of raindrops on undisturbed soil samples.<br>Objetivou-se neste trabalho comparar a desagregação de amostras de solo indeformadas pela energia ultra-sônica com a desagregação causada pela energia cinética de gotas de chuva simulada, estabelecer equações para descrever essa relação e avaliar se a estabilidade de agregados determinada pelas curvas de desagregação por ultra-som pode ser usada para estimar o efeito que as gotas de chuva têm sobre amostras indeformadas. Amostras indeformadas dos horizontes A, Bi e C de um Cambissolo Háplico foram submetidas a diferentes níveis de energia ultra-sônica e gotas de chuva simulada. Amostras peneiradas (agregados) também foram submetidas a diferentes níveis de energia ultra-sônica para obtenção de curvas de desagregação. Os resultados mostraram que a quantidade de solo desagregado pelo impacto das gotas de chuva pode ser simulada pela aplicação de energia ultra-sônica sobre amostras indeformadas de solo. Curvas de desagregação de amostras deformadas não podem ser usadas para estimar o efeito das gotas de chuva sobre amostras indeformadas de solo